Hi!

As strategic corporate affairs advisors, we’re expected to earn trust across various stakeholders – from colleagues and executives to regulators, journalists, patients, investors, and the broader public.

And those relationships ultimately shape our ability to lead, influence, and respond.

But, whether navigating sensitive issues or simply keeping a program on track, we often face similar roadblocks: limited access, shifting priorities, and the need to quickly find common ground.

So, we’re tackling this complex topic head-on in our next Comm Convo: The Trust Exchange, on Tuesday, April 29th at 1-2 p.m. ET.

Led by Kris Baum (former FDA, CDER), Mary Kosinski (FleishmanHillard), and Sarah Spencer (Vor Bio), this session will open a practical discussion about strengthening the relationships that matter most, both inside and outside your organization:

• Lead conversations with C-suite executives that establish communications as a strategic function, even when time and attention are limited.
• Build credibility with technical teams and research leaders by asking the right questions and surfacing the information you need.
• Guide your communications team in creating and maintaining trust across diverse functions and audiences, especially during times of transition.
• Strengthen our profession’s role as trusted counsel through sharper strategies for relationship-building with stakeholders across the healthcare and biopharma ecosystem.

Sign up here:

T2B Pro & Student members (FREE): Log in to your account, and get your promo code here.​

T2B Basic members ($40): RSVP and secure your place here.​

Our April Comm Convo speakers

For this topic especially, it’s critical that we’re able to provide you with a range of perspectives, which is why we’ve selected three speakers with varied backgrounds for this session.

Kris Baum was one of the many comms leaders affected by the recent changes in Washington. As former Director of Health Communication at the FDA’s Center for Drug Evaluation and Research (CDER), he will provide us with a government perspective, addressing the disasters that are happening right now and the potential risk of trust degradation at the intersections between the government, patient communities, the general public, and industry.

Sarah Spencer will bring the in-house perspective, drawing on 25+ years leading communications in biopharma and currently overseeing corporate comms and IR at Vor Bio. She’ll share how she’s built trust during moments that matter, like leading messaging through a company rebrand, securing financing, and guiding internal engagement. From public company dynamics to executive storytelling, she’ll reflect on lessons learned across roles at GSK, Audentes Therapeutics (acquired by Astellas), and in biotech consulting.

And, as the Global Managing Director of Health and Life Sciences at FleishmanHillard, Mary Kosinski can speak to the agency partner perspective based on decades navigating trust in high-stakes environments. With a background that spans HHS, BARDA, and CMS — alongside biopharma industry leadership — Mary will offer guidance on forging credibility across public and private sectors, coordinating complex coalitions, and counseling clients during moments of uncertainty and change.

We hope you’ll join us for this timely conversation, which we know will provide you with actionable strategies that you can apply immediately to strengthen trust where it matters most.

Lynnea

P.S: Tickets to all of our events (both online and in-person) are included as part of the T2B Pro membership. If you plan to attend many of these sessions, becoming a T2B Pro member for $1,000 per year is better value than buying individual a la carte tickets.

​

​